Researchers at Spain’s Universidad Miguel Hernández (UMH) in Elche have announced that they have developed a stem-cell treatment which can decrease the mortality rate in Covid-19 sufferers who are in a critical condition from the current average of 85 percent to 15 percent.
The treatment was given to 13 Covid-19 patients who had been admitted to the ICU, were on a ventilator and had not responded favourably to conventional treatments.
All but two patients responded favourably to the medication, with a generalised clinical and radiological (X-ray results) improvement and no side effects detected.
In fact, the results suggest that the new treatment increases the presence of T lymphocytes – immune response cells which attack the virus – and B lymphocytes which synthesize the appropriate antibodies.
Most of the patients were taken off the ventilator during the data collection period, which reflects the marked improvement in their condition.
The treatment, dubbed the BALMYS-19 project, has seen six other universities take part as well as six Spanish hospitals.
Their research has been published in the prestigious medical journal The Lancet.
This all-Spanish Covid-19 treatment is based on stem cells with regenerative, anti-inflammatory and immunoregulatory properties.